Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: Phase III study in patients at risk for NSAID-associated gastric ulcers

Current Medical Research and Opinion

Volumn 27, Issue 4, 2011, Pages 847-854

  Sostek, Mark B ^a   Fort, John G ^b   Estborn, Lennart ^c   Vikman, Kerstin ^c  

^a ASTRAZENECA   (United Kingdom)

^b POZEN Inc   (United States)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Drug combinations; Drug safety; Esomeprazole; Long term; Naproxen; NSAIDs; Upper gastrointestinal

Indexed keywords

ANTACID AGENT; ESOMEPRAZOLE PLUS NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTHRALGIA; ARTICLE; ATRIOVENTRICULAR BLOCK; BACKACHE; CANCER RISK; CAROTID ARTERY OBSTRUCTION; CLINICAL EVALUATION; CONSTIPATION; CONTROLLED STUDY; CONTUSION; CORONARY ARTERY DISEASE; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; LOWER ABDOMINAL PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NECROTIZING FASCIITIS; OSTEOARTHRITIS; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PREVALENCE; RHEUMATOID ARTHRITIS; SINUSITIS; STAPHYLOCOCCUS INFECTION; STOMACH ULCER; THORAX PAIN; THYROID CANCER; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ARTHRITIS, RHEUMATOID; DOSAGE FORMS; DRUG COMBINATIONS; FEMALE; HUMANS; MAGNESIUM COMPOUNDS; MALE; MIDDLE AGED; NAPROXEN; OMEPRAZOLE; OSTEOARTHRITIS; RISK FACTORS; STOMACH ULCER; TIME FACTORS;

EID: 79952650345     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.555756     Document Type: Article

References (33)

1. Chan FKL, Abraham NS, Scheiman JM, et al. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the first international working party on gastrointestinal and cardiovascular effects of nonsteroidal anti-inflammatory drugs and anti-platelet agents. Am J Gastroenterol 2008;103:2908-18
2. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120:594-606 (Pubitemid 32171634)
3. Lanza FL, Chan FK, Quigley EMM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009;104:728-38
4. Laine L, Bombardier C, Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002;123:1006-12
5. Rahme E, Nedjar H, Bizzi A, et al. Hospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among patients 50 years or older also using non-steroidal anti-inflammatory drugs: a retrospective cohort study. Aliment Pharmacol Ther 2007;26:1387-98 (Pubitemid 350045614)
6. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 Expert Consensus Document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008;118:1894-909
7. Desai SP, Solomon DH, Abramson SP, et al. Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper. Arthritis Rheum 2008;59: 1058-73
8. National Institute for Health and Clinical Excellence. The care and management of osteoarthritis in adults. NICE clinical guideline 59 [online]. Available from http://www.nice.org.uk/nicemedia/pdf/CG59NICEguideline.pdf [Accessed 3 Jun 2010]
9. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137-62 (Pubitemid 351222155)
10. Abraham NS, El-Serag HB, Johnson ML, et al. National adherence to evidence- based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology 2005;129:1171-8 (Pubitemid 41446857)
11. Sturkenboom MCJM, Burke TA, Dieleman JP, et al. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology (Oxford) 2003;42 (Suppl 3):iii23-31
12. Goldstein JL, Howard KB, Walton SM, et al. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. Clin Gastroenterol Hepatol 2006;4:1337-45
13. Sturkenboom MCJM, Burke TA, Tangelder MJD, et al. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2003;18:1137-47 (Pubitemid 38021600)
14. van Soest EM, Sturkenboom MCJM, Dieleman JP, et al. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther 2007;26:265-75 (Pubitemid 46985490)
15. Miner Jr P, Plachetka J, Orlemans E, et al. Clinical trial: evaluation of gastric acid suppression with three doses of immediate-release esomeprazole in the fixed-dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric-coated esomeprazole 20 mg: a randomised, open-label, Phase I study in healthy volunteers. Aliment Pharmacol Ther 2010;32:414-24
16. Hochberg M, Cryer B, Fort JG, et al. A fixed-dose combination of naproxen and esomeprazole magnesium (VIMOVOTM) has comparable efficacy and tolerability to celecoxib in patients with osteoarthritis (OA) of the knee: results from two randomized, controlled trials. Arthritis Rheum 2010;62 (Suppl 10): S388, abs 937
17. Goldstein JL, Hochberg MC, Fort JG, et al. Clinical trial: incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone. Aliment Pharmacol Ther 2010;32:401-13
18. Electronic Medicines Compendium (eMC). Summary of Product Characteristics. VIMOVO 500 mg/20 mg modified-release tablets [online]. Available from http://www.medicines.org.uk/EMC/medicine/23883/SPC/ VIMOVO+500+mg+20+mg+modified-release+tablets [Accessed 19 Nov 2010]
19. Food and Drug Administration (FDA). VIMOVOTM prescribing information [online]. Available from http://www.accessdata.fda.gov/drugsatfda-docs/ label/2010/022511lbl.pdf [Accessed 9 Jun 2010]
20. Pfizer Inc. PhRMA Clinical Study Synopsis: a multi-center, double-blind, parallel group study comparing the incidence of clinically significant upper gastrointestinal events between celecoxib 400 mg BID, and ibuprofen 800 mg TID (N49-98-02-035) or diclofenac 75 mg BID (N49-98-02-102) [online]. Available from http://www.clinicalstudyresults.org/documents/companystudy- 1841-0.pdf [Accessed 7 Oct 2010]
21. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55
22. Davies M, Wilton LV, Shakir SA. Safety profile of esomeprazole: results of a prescription-event monitoring study of 11 595 patients in England. Drug Saf 2008;31:313-23 (Pubitemid 351441579)
23. Kale-Pradhan PB, Landry HK, Sypula WT. Esomeprazole for acid peptic disorders. Ann Pharmacother 2002;36:655-63 (Pubitemid 34270283)
24. Maton PN, Vakil NB, Levine JG, et al. Safety and efficacy of long term esomeprazole therapy in patients with healed erosive oesophagitis. Drug Saf 2001;24:625-35 (Pubitemid 32656075)
25. Straus WL, Ofman JJ, MacLean C, et al. Do NSAIDs cause dyspepsia? A meta-analysis evaluating alternative dyspepsia definitions. Am J Gastroenterol 2002;97:1951-8
26. Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006;101:701-10
27. Sultan N, Nazareno J, Gregor J. Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials. Can J Gastroenterol 2008;22:761-6
28. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8
29. Boers M, Tangelder MJ, van Ingen H, et al. The rate of NSAID-induced endoscopic ulcers increases linearly but not exponentially with age: a pooled analysis of 12 randomised trials. Ann Rheum Dis 2007;66:417-18 (Pubitemid 46579647)
30. Centers for Disease Control and Prevention (CDC). Prevalence of Doctor- Diagnosed Arthritis and Arthritis-Attributable Activity Limitation - United States, 2007-2009. Morbidity and Mortality Weekly Report [online]. Available from http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5939a1. htm [Accessed 25 Oct 2010]
31. Hawkey CJ, Cullen DJE, Pearson G, et al. Pharmacoepidemiology of nonsteroidal anti-inflammatory drug use in Nottingham general practices. Aliment Pharmacol Ther 2000;14:177-85 (Pubitemid 30088294)
32. Goldstein JL, Fort JG, Zhang Y, et al. Is age a predictor of endoscopic gastric ulcers in patients taking chronic NSAIDs? A pooled analysis including 854 patients from two phase 3 studies comparing PN400 and enteric-coated naproxen. Ann Rheum Dis 2010;69 (Suppl 3):287, abs THU0430
33. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332:1302-8